FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Mazur Leonard L		 2. Issuer Name and Ticker or Trading Symbol

Citius Pharmaceuticals, Inc. [ CTXR ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Executive Chairman
(Last)          (First)          (Middle)

C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR		 3. Date of Earliest Transaction (MM/DD/YYYY)

10/8/2019
(Street)

CRANFORD, NJ 07016
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                 10255343  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options to Purchase Common Stock (1) $3.45                   (1) 9/13/2027  Common Stock  40000    40000  D   
Warrant to Purchase Common Stock (2) $6.15                   (2) 6/12/2019  Common Stock  19614    19614  D   
Warrant to Purchase Common Stock (2) $9.9                   (2) 9/30/2019  Common Stock  3171    3171  D   
Warrant to Purchase Common Stock (2) $9.9                   (2) 1/8/2020  Common Stock  4984    4984  D   
Warrant to Purchase Common Stock (2) $7.5                   (2) 8/18/2020  Common Stock  35211    35211  D   
Warrant to Purchase Common Stock (2) $7.5                   (2) 11/2/2020  Common Stock  20783    20783  D   
Warrant to Purchase Common Stock (2) $7.5                   (2) 11/20/2020  Common Stock  20664    20664  D   
Warrant to Purchase Common Stock (2) $7.5                   (2) 1/8/2021  Common Stock  13679    13679  D   
Warrant to Purchase Common Stock (2) $7.5                   (2) 3/14/2021  Common Stock  4210    4210  D   
Warrant to Purchase Common Stock (2) $6.15                   (2) 3/15/2021  Common Stock  18106    18106  D   
Warrant to Purchase Common Stock  $4.125                   (2) 8/8/2022  Common Stock  421400    421400  D   
Warrant to Purchase Common Stock  $4.125                   (2) 8/8/2022  Common Stock  11000    11000  D   
Options to Purchase Common Stock (3) $6.75                   (3) 9/12/2024  Common Stock  220000    220000  D   
Warrant to Purchase Common Stock (2) $4.63                   (2) 6/19/2023  Common Stock  106553    106553  D   
Warrant to Purchase Common Stock (2) $2.86                   (2) 9/29/2023  Common Stock  167504    167504  D   
Warrant to Purchase Common Stock (2) $1.15                   (2) 8/14/2023  Common Stock  3137255    3137255 (4) D   
Options to Purchase Common Stock (5) $1.62                   (5) 9/4/2028  Common Stock  150000    150000  D   
Warrant to Purchase Common Stock (2) $1.42                   (2) 4/5/2021  Common Stock  1165048    1615048 (4) D   
Warrant to Purchase Common Stock (2) $0.77                   (2) 9/27/2024  Common Stock  2234700    2234700 (4) D   
Options to Purchase Common Stock  $0.67  10/8/2019    A     175000       (6) 10/8/2029  Common Stock  175000  $0  175000  D   

Explanation of Responses:
(1)  One-third of the shares of the Company's common stock underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of the Company's common stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest, provided the Reporting Person continues to serve as a member of the Company's Board of Directors as of each such vesting date.
(2)  The warrant is fully vested and exercisable immediately.
(3)  The option vested as to 40% of the shares of the Company's common stock on September 12, 2014 and 15% of the shares on each of September 12, 2015, March 12 and September 12, 2016 and September 12, 2017.
(4)  The purchase price of the warrants was included in the purchase price of the common stock reported in Table I.
(5)  One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date.
(6)  The options were granted on October 8, 2019. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Mazur Leonard L
C/O CITIUS PHARMACEUTICALS, INC.
11 COMMERCE DRIVE, 1ST FLOOR
CRANFORD, NJ 07016 		X X Executive Chairman

Signatures
/s/ Alexander M. Donaldson, by power of attorney 10/10/2019
**Signature of Reporting Person Date


Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Citius Pharmaceuticals Charts.
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Citius Pharmaceuticals Charts.
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....